Clinical use of erythropoietin.
Recombinant human erythropoietin has been available for clinical use since 1985. It was an immediate success in treating the anemia of chronic renal failure and has also enjoyed some objective success in the treatment of other anemias in either a therapeutic or prophylactic setting, but the issues of appropriate patient selection and cost-benefit ratios are still unresolved. This review discusses the most recent literature concerning the use of recombinant human erythropoietin for the anemia associated with cancer, HIV infection, myelodysplasia, prematurity, autologous blood transfusion, bone marrow transplantation, and chronic renal failure.
Henry
D H
DH
Graduate Hospital, Philadelphia, Pennsylvania, USA.
Spivak
J L
JL
D000740:Anemia / Q000188:drug therapy; D001804:Blood Transfusion, Autologous / Q000379:methods; D004921:Erythropoietin / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D009190:Myelodysplastic Syndromes / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin